A Tripeptide Deletion in the Class C beta-Lactamase FOX-4 Enzyme Impairs Cefoxitin Hydrolysis and Slightly Increases Susceptibility to beta-Lactamase Inhibitors
Mallo, Susana; Pérez-Llarena, Francisco J.; Kerff, Frédéricet al.
2010 • In Journal of Antimicrobial Chemotherapy, 65 (6), p. 1187-94
[en] OBJECTIVES: A natural variant of the AmpC enzyme from Escherichia coli HKY28 with a tripeptide deletion (Gly-286/Ser-287/Asp-288) was recently described. The isolate produced an inhibitor-sensitive AmpC beta-lactamase variant that also conferred higher than usual levels of resistance to ceftazidime in the E. coli host. To demonstrate whether this is true in other class C beta-lactamase enzymes, we deleted the equivalent tripeptide in the FOX-4 plasmid-mediated class C beta-lactamase.
METHODS: By site-directed mutagenesis, we deleted the tripeptide Gly-306/Asn-307/Ser-308 of FOX-4, thus generating FOX-4(DeltaGNS). The enzymes (FOX-4 wild-type and DeltaGNS) were purified and kinetic parameters (kcat, Km, kcat/Km) as well as IC50 values of several beta-lactams were assessed. Modelling studies were also performed.
RESULTS: FOX-4(DeltaGNS) did not increase the catalytic efficiency towards ceftazidime, although it conferred a slight increase in the susceptibility to beta-lactamase inhibitors. There was also a noteworthy decrease in the cefoxitin MIC with the FOX-4(DeltaGNS) mutant (from 512 to 16 mg/L) as well as a 10-fold decrease in kcat/Km towards imipenem, which revealed specific structural features.
CONCLUSIONS: Although deletions in the R2-loop are able to extend the substrate spectrum of class C enzymes, the present results do not confirm this hypothesis in FOX-4. The FOX-4 R2 site would already be wide enough to accommodate antibiotic molecules, and thus any amino acid replacement or deletion at this location would not affect the hydrolytic efficiency towards beta-lactams and would have a less drastic effect on the susceptibility to beta-lactamase inhibitors.
Research Center/Unit :
CIP - Centre d'Ingénierie des Protéines - ULiège
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Mallo, Susana
Pérez-Llarena, Francisco J.
Kerff, Frédéric ; Université de Liège - ULiège > Centre d'ingénierie des protéines
Fernández-Moreira, Esteban
Soares, Nelson C.
Galleni, Moreno ; Université de Liège - ULiège > Département des sciences de la vie > Macromolécules biologiques
Bou, German
Language :
English
Title :
A Tripeptide Deletion in the Class C beta-Lactamase FOX-4 Enzyme Impairs Cefoxitin Hydrolysis and Slightly Increases Susceptibility to beta-Lactamase Inhibitors
Beceiro A, Bou G. Class C β-lactamases: an increasing problem worldwide. Rev Med Microb 2004; 15: 141-52.
Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289: 321-31.
Barnaud G, Labia R, Raskine L et al. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol Lett 2001; 195: 185-90.
Pérez-Pérez F, Hanson ND. Detection of plasmid-mediated AmpC (-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-62.
Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed class I (-lactamases. J Antimicrob Chemother 1990; 25: 199-208.
Bush K, Macalintal C, Rasmussen BA et al. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 1993; 37: 851-8.
Crichlow GV, Kuzin AP, Nukaga M et al. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 1999; 38: 10256-61.
Sohn SG, Lee JJ, Sohn ES et al. Comment on: extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J Antimicrob Chemother 2008; 61: 965-6.
Doi Y, Wachino J, Ishiguro M et al. Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob Agents Chemother 2004; 48: 2652-8.
Yamaguchi Y, Sato G, Yamagata Y et al. Structure of AmpC (-lactamase (AmpCD)froman Escherichia coli clinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009; 65: 540-3.
Mammeri H, Poirel L, Bemer P et al. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004; 48: 716-20.
Kim JY, Jung HI, An YJ et al. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol Microbiol 2006; 60: 907-16.
Mammeri H, Poirel L, Nordmann P. Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. Antimicrob Agents Chemother 2007; 60: 490-4.
Wachino J, Kurokawa H, Suzuki S et al. Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob Agents Chemother 2006; 50: 534-41.
Barnaud G, Benzerara Y, Gravisse J et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004; 48: 1040-2.
Bou G, Oliver A, Ojeda M et al. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated β-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother 2000; 44: 2549-53.
Ho SN, Hunt HD, Horton RM et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77:51-9.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
Sirot D, Recule C, Chaibi EB et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997; 41: 1322-5.
Mereghetti P, Ganadu ML, Papaleo E et al. Validation of protein models by a neural network approach. BMC Bioinformatics 2008; 9: 66.
Beadle BM, Shoichet BK. Structural basis for imipenem inhibition of class C β-lactamases. Antimicrob Agents Chemother 2002; 46: 3978-80.
